ASX Growth Companies With High Insider Ownership For October 2024

As the Australian market navigates a period of mixed performance, with the ASX200 showing slight declines and sectors like Real Estate outperforming others, investors are closely watching commodity prices driven by bullish expectations around Chinese stimulus. In this context, growth companies with high insider ownership can be particularly appealing as they may offer aligned interests between management and shareholders, potentially providing resilience amidst fluctuating market conditions.

Top 10 Growth Companies With High Insider Ownership In Australia

Name	Insider Ownership	Earnings Growth
Clinuvel Pharmaceuticals (ASX:CUV)	10.4%	27.4%
Catalyst Metals (ASX:CYL)	17%	54.5%
Genmin (ASX:GEN)	12%	117.7%
Hillgrove Resources (ASX:HGO)	10.4%	71.5%
AVA Risk Group (ASX:AVA)	15.7%	118.8%
Pointerra (ASX:3DP)	20.1%	126.4%
Liontown Resources (ASX:LTR)	14.7%	60.7%
Acrux (ASX:ACR)	17.4%	91.6%
Adveritas (ASX:AV1)	21.1%	144.2%
Plenti Group (ASX:PLT)	12.8%	106.4%

Click here to see the full list of 99 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Catalyst Metals (ASX:CYL)

Simply Wall St Growth Rating: ★★★★★★

Overview: Catalyst Metals Limited is engaged in the exploration and evaluation of mineral properties in Australia, with a market cap of A$636.71 million.

Operations: The company's revenue segments include A$75.08 million from Tasmania and A$243.77 million from Western Australia.

Insider Ownership: 17%

Catalyst Metals, recently added to the S&P/ASX Emerging Companies Index, shows strong growth potential with forecasted revenue and earnings growth significantly outpacing the Australian market. The company reported A$317.01 million in sales for FY2024, a substantial increase from the previous year. Despite no recent insider trading activity, Catalyst's strategic developments at Plutonic East and Trident support its organic growth profile while maintaining a focus on economic extraction prospects.

• Click here and access our complete growth analysis report to understand the dynamics of Catalyst Metals.
• According our valuation report, there's an indication that Catalyst Metals' share price might be on the cheaper side.

Mineral Resources (ASX:MIN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Mineral Resources Limited operates as a mining services company with operations in Australia, Asia, and internationally, and has a market cap of A$10.40 billion.

Operations: The company's revenue segments comprise A$16 million from Energy, A$1.41 billion from Lithium, A$2.58 billion from Iron Ore, and A$3.38 billion from Mining Services, along with A$19 million from Other Commodities.

Insider Ownership: 11.7%

Mineral Resources is experiencing moderate growth with forecasted earnings expansion of 38% annually, surpassing the Australian market's average. Despite lower profit margins and interest coverage challenges, insider activity shows more buying than selling recently. The company is exploring asset sales in the Perth Basin to strengthen its balance sheet amid high net debt of A$4.4 billion. Recent M&A discussions highlight strategic efforts to fund projects like the Onslow iron ore initiative while considering joint ventures and financing options.

• Get an in-depth perspective on Mineral Resources' performance by reading our analyst estimates report here.
• Our comprehensive valuation report raises the possibility that Mineral Resources is priced higher than what may be justified by its financials.

Mesoblast (ASX:MSB)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited develops regenerative medicine products across Australia, the United States, Singapore, and Switzerland with a market cap of A$1.70 billion.

Operations: The company generates revenue of $5.90 million from its cell technology platform development for commercialization.

Insider Ownership: 22.2%

Mesoblast, with substantial insider buying and no recent significant sales, is positioned for rapid growth. The company forecasts revenue growth of 45.8% annually, far outpacing the Australian market average. Despite a net loss of US$87.96 million in 2024 and being dropped from the S&P/ASX Emerging Companies Index, Mesoblast's convertible note issuance for A$72.7 million supports its financial strategy amidst FDA review milestones for Ryoncil in treating SR-aGVHD in children.

• Unlock comprehensive insights into our analysis of Mesoblast stock in this growth report.
• Our valuation report unveils the possibility Mesoblast's shares may be trading at a discount.

Make It Happen

• Embark on your investment journey to our 99 Fast Growing ASX Companies With High Insider Ownership selection here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com